RNA m6A Methylation Promotes Tumor Development and WASF3 Translation in Esophageal Squamous Cell Carcinoma

Abstract

Esophageal squamous cell carcinoma (ESCC) tissues exhibit abnormal N6-methyladenosine (m6A) modification and regulator levels, but the specific effects of this dysregulation on ESCC remain unclear. WASF3 levels were significantly elevated in ESCC tissues, and ESCC patients with high WASF3 expression had significantly worse prognosis. WASF3 suppressed the proliferation of ESCC cells and inhibited colony formation and cell cycle progression. Mechanistically, METTL3 interacted with WASF3 and mediated m6A modification of its mRNA. Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) enhanced WASF3 translation by binding to the m6A site in its 3′ untranslated region, and highly expressed WASF3 activated the mitogen-activated protein kinase (MAPK) signaling pathway by interacting with phosphorylated p38 (p-p38), thereby promoting ESCC progression. Moreover, removal of the m6A modification of WASF3 mRNA inhibited WASF3 expression, ESCC cell proliferation, and abolished the ability of WASF3 to bind to p-p38 and activate MAPK signaling. LNP small interfering RNA targeting WASF3, both alone and in combination with paclitaxel, could successfully suppress ESCC tumorigenesis. Our findings demonstrate that WASF3 plays a pivotal role in ESCC and highlight the functional significance of the METTL3/m6A/WASF3/IGF2BP2 axis in regulating ESCC progression, which could facilitate the development of novel prognostic and therapeutic targets for ESCC.

Keywords

WASF3 / esophageal squamous cell carcinoma / m6A methylation / METTL3 / IGF2BP2 / lipid nanoparticles

References

[1] A. Leiter, R. R. Veluswamy, and J. P. Wisnivesky, “The Global Burden of Lung Cancer: Current Status and Future Trends,” Nature Reviews Clinical Oncology 20 (2023): 624-639.

[2] E. Morgan, I. Soerjomataram, H. Rumgay, et al., “The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020,” Gastroenterology 163 (2022): 649.e2-58.e2.

[3] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer Statistics, 2019,” CA: A Cancer Journal for Clinicians 69 (2019): 7-34.

[4] M. Arnold, I. Soerjomataram, J. Ferlay, and D. Forman, “Global Incidence of Oesophageal Cancer by Histological Subtype in 2012,” Gut 64 (2015): 381-387.

[5] J. Chen, F. Wu, H. L. Pei, et al., “Analysis of the Correlation Between P53 and Cox-2 Expression and Prognosis in Esophageal Cancer,” Oncology Letters 10 (2015): 2197-2203.

[6] G. Q. Wang, G. G. Jiao, F. B. Chang, et al., “Long-term Results of Operation for 420 Patients With Early Squamous Cell Esophageal Carcinoma Discovered by Screening,” Annals of Thoracic Surgery 77 (2004): 1740-1744.

[7] S. E. Kane and K. Beemon, “Precise Localization of m6A in Rous Sarcoma Virus RNA Reveals Clustering of Methylation Sites: Implications for RNA Processing,” Molecular and Cellular Biology 5 (1985): 2298-2306.

[8] S. Zhang, “Mechanism of N6-methyladenosine Modification and Its Emerging Role in Cancer,” Pharmacology & Therapeutics 189 (2018): 173-183.

[9] N. Liu, Q. Dai, G. Zheng, C. He, M. Parisien, and T. Pan, “N(6)-methyladenosine-dependent RNA Structural Switches Regulate RNA-protein Interactions,” Nature 518 (2015): 560-564.

[10] K. D. Meyer and S. R. Jaffrey, “Rethinking m6A Readers, Writers, and Erasers,” Annual Review of Cell and Developmental Biology 33 (2017): 319-342.

[11] H. Huang, H. Weng, W. Sun, et al., “Recognition of RNA N(6)-methyladenosine by IGF2BP Proteins Enhances mRNA Stability and Translation,” Nature Cell Biology 20 (2018): 285-295.

[12] X. Wang, Z. Lu, A. Gomez, et al., “N6-methyladenosine-dependent Regulation of Messenger RNA Stability,” Nature 505 (2014): 117-120.

[13] M. Li, M. Li, Y. Xia, et al., “HDAC1/3-dependent Moderate Liquid-liquid Phase Separation of YY1 Promotes METTL3 Expression and AML Cell Proliferation,” Cell Death & Disease 13 (2022): 992.

[14] D. Lv, R. C. Gimple, C. Zhong, et al., “PDGF Signaling Inhibits Mitophagy in Glioblastoma Stem Cells Through N6-methyladenosine,” Developmental Cell 57 (2022): 1466.e6-81.e6.

[15] K. Suphakhong, M. Terashima, S. Wanna-Udom, et al., “m6A RNA Methylation Regulates the Transcription Factors JUN and JUNB in TGF-β-induced Epithelial-mesenchymal Transition of Lung Cancer Cells,” Journal of Biological Chemistry 298 (2022): 102554.

[16] K. Sossey-Alaoui, X. Li, T. A. Ranalli, and J. K. Cowell, “WAVE3-mediated Cell Migration and Lamellipodia Formation Are Regulated Downstream of Phosphatidylinositol 3-kinase,” Journal of Biological Chemistry 280 (2005): 21748-21755.

[17] Y. Teng, M. Q. Ren, R. Cheney, S. Sharma, and J. K. Cowell, “Inactivation of the WASF3 Gene in Prostate Cancer Cells Leads to Suppression of Tumorigenicity and Metastases,” British Journal of Cancer 103 (2010): 1066-1075.

[18] S. Kurisu and T. Takenawa, “The WASP and WAVE family Proteins,” Genome Biology 10 (2009): 226.

[19] Y. Teng, M. Liu, and J. K. Cowell, “Functional Interrelationship Between the WASF3 and KISS1 Metastasis-associated Genes in Breast Cancer Cells,” International Journal of Cancer 129 (2011): 2825-2835.

[20] H. Qin, S. Lu, M. Thangaraju, and J. K. Cowell, “Wasf3 deficiency Reveals Involvement in Metastasis in a Mouse Model of Breast Cancer,” American Journal of Pathology 189 (2019): 2450-2458.

[21] S. Huang, C. Huang, W. Chen, et al., “WAVE3 promotes Proliferation, Migration and Invasion via the AKT Pathway in Pancreatic Cancer,” International Journal of Oncology 53 (2018): 672-684.

[22] U. Kansakar, W. Wang, V. Markovic, and K. Sossey-Alaoui, “Phosphorylation of the Proline-rich Domain of WAVE3 Drives Its Oncogenic Activity in Breast Cancer,” Scientific Reports 11 (2021): 3868.

[23] X. Li, J. Geng, Z. Ren, C. Xiong, Y. Li, and H. Liu, “WAVE3 upregulation in Esophageal Squamous Cell Carcinoma and Its Effect on the Migration of human Esophageal Cancer Cell Lines in Vitro,” Molecular Medicine Reports 22 (2020): 465-473.

[24] W. Wang, F. Shao, X. Yang, et al., “METTL3 promotes Tumor Development by Decreasing APC Expression Mediated by APC mRNA N6-methyladenosine-dependent YTHDF Binding,” Nature Communications 12 (2021): 3803.

[25] C. R. Alarcón, H. Lee, H. Goodarzi, N. Halberg, and S. F. Tavazoie, “N6-methyladenosine Marks Primary microRNAs for Processing,” Nature 519 (2015): 482-485.

[26] C. B. Roces, G. Lou, N. Jain, et al., “Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics,” Pharmaceutics 12 (2020): 1095.

[27] J. A. Kulkarni, P. R. Cullis, and R. van der Meel, “Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility,” Nucleic Acid Therapeutics 28 (2018): 146-157.

[28] A. Akinc, M. A. Maier, M. Manoharan, et al., “The Onpattro Story and the Clinical Translation of Nanomedicines Containing Nucleic Acid-based Drugs,” Nature Nanotechnology 14 (2019): 1084-1087.

[29] T. Yanagi, K. Tachikawa, R. Wilkie-Grantham, et al., “Lipid Nanoparticle-mediated siRNA Transfer Against PCTAIRE1/PCTK1/Cdk16 Inhibits in Vivo Cancer Growth,” Molecular Therapy Nucleic Acids 5 (2016): e327.

[30] Q. Lan, P. Y. Liu, J. Haase, J. Bell, S. Hüttelmaier, and T. Liu, “The Critical Role of RNA m6A Methylation in Cancer,” Cancer Research 79 (2019): 1285-1292.

[31] Y. Yang, F. Shen, W. Huang, et al., “Glucose Is Involved in the Dynamic Regulation of m6A in Patients With Type 2 Diabetes,” Journal of Clinical Endocrinology and Metabolism 104 (2019): 665-673.

[32] P. Mathiyalagan, M. Adamiak, J. Mayourian, et al., “FTO-dependent N6-methyladenosine Regulates Cardiac Function During Remodeling and Repair,” Circulation 139 (2019): 518-532.

[33] H. Huang, H. Weng, and J. Chen, “mA Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer,” Cancer Cell 37 (2020): 270-288.

[34] S. Geula, S. Moshitch-Moshkovitz, D. Dominissini, et al., “m6A mRNA Methylation Facilitates Resolution of Naive Pluripotency Toward Differentiation,” Science 347 (2015): 1002-1006.

[35] P. Wang, K. A. Doxtader, and Y. Nam, “Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases,” Molecular Cell 63 (2016): 306-317.

[36] S. Rauch, C. He, and B. C. Dickinson, “Targeted M(6)A Reader Proteins to Study Epitranscriptomic Regulation of Single RNAs,” Journal of the American Chemical Society 140 (2018): 11974-11981.

[37] R. Li, L. Zeng, H. Zhao, et al., “ATXN2-mediated Translation of TNFR1 Promotes Esophageal Squamous Cell Carcinoma via m6A-dependent Manner,” Molecular Therapy 30 (2022): 1089-1103.

[38] S. Li, Z. Zhuang, T. Wu, et al., “Nicotinamide Nucleotide Transhydrogenase-mediated Redox Homeostasis Promotes Tumor Growth and Metastasis in Gastric Cancer,” Redox Biology 18 (2018): 246-255.

[39] J. Zhou, J. Wan, X. Gao, X. Zhang, S. R. Jaffrey, and S. B. Qian, “Dynamic M(6)A mRNA Methylation Directs Translational Control of Heat Shock Response,” Nature 526 (2015): 591-594.

[40] X. Wang, B. S. Zhao, I. A. Roundtree, et al., “N6-methyladenosine Modulates Messenger RNA Translation Efficiency,” Cell 161 (2015): 1388-1399.

[41] A. Cuenda and J. J. Sanz-Ezquerro, “p38gamma and p38delta: From Spectators to Key Physiological Players,” Trends in Biochemical Sciences 42 (2017): 431-442.

[42] E. A. Bonney, “Mapping out p38MAPK,” American Journal of Reproductive Immunology 77 (2017): e12652.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.